Kenia - englanti - Pharmacy and Poisons Board

vildagliptin 50mg metformin hydrochloride 500mg - coated tablet - vildagliptin 50mg metformin hydrochloride 500mg - metformin and vildagliptin

Kenia - englanti - Pharmacy and Poisons Board

vildagliptin 50mg metformin hydrochloride 850mg - coated tablet - vildagliptin 50mg metformin hydrochloride 850mg - metformin and vildagliptin

Kenia - englanti - Pharmacy and Poisons Board

vildagliptin inn & metformin hydrochloride bp - tablet - vildagliptin 50 mg & metformin hydrochloride 500… - metformin and vildagliptin

Kenia - englanti - Pharmacy and Poisons Board

vildagliptin inn & metformin hydrochloride bp - tablet - vildagliptin 50 mg & metformin hydrochloride 850… - metformin and vildagliptin

Kenia - englanti - Pharmacy and Poisons Board

vildagliptin and metformin hydrochloride bp - film-coated tablet - vildagliptin 50 mg / tablet , metformin… - metformin and vildagliptin

Israel - englanti - Ministry of Health

novartis israel ltd - metformin hydrochloride; vildagliptin - film coated tablets - metformin hydrochloride 1000 mg; vildagliptin 50 mg - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus:- eucreas is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.- eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled with metformin and a sulphonylurea.- eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

Israel - englanti - Ministry of Health

novartis israel ltd - metformin hydrochloride; vildagliptin - film coated tablets - metformin hydrochloride 500 mg; vildagliptin 50 mg - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus:- eucreas is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.- eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled with metformin and a sulphonylurea.- eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

Kenia - englanti - Pharmacy and Poisons Board

m/s. innocia lifesciences pvt. ltd. m/s. innocia lifesciences pvt. ltd. 12 balaji - vildagliptin - tablet - each tablet contains: vildagliptin100mg (as… - vildagliptin

Malta - englanti - Medicines Authority

tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - vildagliptin, metformin hydrochloride - film-coated tablet - metformin hydrochloride 850 mg vildagliptin 50 mg - drugs used in diabetes

Kenia - englanti - Pharmacy and Poisons Board

dawa limited plot no.7879/8,baba dogo road - ruaraka,p.o box - vildagliptin - tablet - each tablet contain :vildagliptin 50mg - vildagliptin